A Phase 3 interventional study of Cell culture-derived influenza vaccine and Egg-derived influenza virus vaccine in Influenza, sponsored by Novartis Vaccines. Completed at 56 sites in 3 countries. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-24.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Influenza, Human by Novartis — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novartis.
Among the 101 studies in Influenza, Human by Novartis, this one has the largest enrollment of the 97 interventional ones that give a count, is one of 20 that started in 2007, is one of 39 in phase 3, and was the 33rd registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →None of the 101 studies in Influenza, Human by Novartis is open now. The open studies under Influenza, Human, anywhere →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 48 · Phase 3 45 · Phase 4 5
First in 2004; this study’s year is marked. 20 started in 2007.
This study's enrollment of 11,404 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 97 interventional studies, 4,279 across the 4 observational. Of the 100 that completed or were terminated, 48 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 101 studies in Influenza, Human by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one dose of cell culture-derived influenza vaccine.
Biological: Cell culture-derived influenza vaccine
Subjects received one dose of the trivalent egg-derived influenza vaccine.
Biological: Egg-derived influenza virus vaccine
Subjects received one dose of phosphate buffered solution (PBS).
Biological: Placebo
One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
One dose (0.5 mL) of phosphate buffered solution.
Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains
The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.
Time frame: 6 Months
Number of Subjects With Culture-confirmed Influenza Illness Caused by Non-Vaccine Like Strains
The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.
Time frame: 6 Months
Number of Subjects With Influenza Caused by Vaccine-like and Non-vaccine-like Strains
The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.
Time frame: 6 Months
Influenza-Associated Days in Bed, All Subjects
The number of subjects in this analysis included all subjects in the per protocol efficacy population.
Time frame: 6 Months
Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza
The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.
Time frame: 6 Months
Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects
The number of subjects in this analysis included all subjects in the per protocol efficacy population.
Time frame: 6 Months
Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza
The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.
Time frame: 6 Months
Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects
The number of subjects in this analysis included all subjects in the per protocol efficacy population.
Time frame: 6 Months
Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza
The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.
Time frame: 6 Months
Percentages of Subjects Who Achieved HI Titers ≥40 After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo
Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.
Time frame: Before vaccination (day 1) and three weeks after vaccination (day 22)
Percentages of Subjects Achieving Seroconversion After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo
As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer \<10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.
Time frame: Three weeks after vaccination (day 22)
Number of Subjects Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination
The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.
Time frame: Up to 7 days post vaccination
Participants were enrolled at multiple centres in the US, Poland and Finland.
| Milestone | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Started | 3828 | 3676 | 3900 |
| Completed | 3622 | 3510 | 3712 |
| Not completed | 206 | 166 | 188 |
| Withdrew: Death | 2 | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 7 | 5 |
| Withdrew: Lost to follow-up | 175 | 143 | 170 |
| Withdrew: Inappropriate enrollment | 3 | 6 | 3 |
| Withdrew: Unable to classify | 9 | 4 | 3 |
| Withdrew: Protocol violation | 4 | 5 | 6 |
The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.
| Subjects | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Overall | 7 | 9 | 44 |
| A/Wisconsin/67/2005 (H3N2)-like | 2 | 1 | 0 |
| A/Solomon Islands/3/2006 (H1N1)-like | 5 | 8 | 43 |
| B/Malaysia/2506/2004-like | 0 | 0 | 1 |
The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.
| Subjects | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Overall | 30 | 29 | 74 |
| A/H3N2 | 0 | 2 | 8 |
| A/H1N1 | 1 | 0 | 8 |
| B | 29 | 27 | 59 |
The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.
| Subjects | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Overall | 42 | 49 | 140 |
| A/H3N2 | 6 | 12 | 25 |
| A/H1N1 | 6 | 10 | 57 |
| B | 30 | 27 | 61 |
The number of subjects in this analysis included all subjects in the per protocol efficacy population.
| Number of Days | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Influenza-Associated Days in Bed, All Subjects | 0.04 ± 0.496 | 0.04 ± 0.404 | 0.12 ± 0.777 |
The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.
| Number of Days | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza | 3.9 ± 2.62 | 2.9 ± 1.98 | 3.4 ± 2.4 |
The number of subjects in this analysis included all subjects in the per protocol efficacy population.
| Number of Medical Visits | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects | 0.01 ± 0.138 | 0.01 ± 0.134 | 0.03 ± 0.262 |
The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.
| Number of Medical Visits | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza | 0.8 ± 0.92 | 0.6 ± 1.0 | 0.8 ± 1.16 |
The number of subjects in this analysis included all subjects in the per protocol efficacy population.
| Numebr of Days of Usual Activity Lost | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects | 0.06 ± 0.635 | 0.05 ± 0.605 | 0.16 ± 1.006 |
The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.
| Numebr of Days of Usual Activity Lost | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza | 5.1 ± 3.41 | 4.0 ± 3.4 | 4.6 ± 3.45 |
Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.
| Percentages of subjects | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| A/H1N1 - Day 1 | 48 (42 to 55) | 53 (49 to 57) | 60 (46 to 73) |
| A/H1N1 - Day 22 | 99 (97 to 100) | 98 (97 to 99) | 60 (46 to 73) |
| A/H3N2 - Day 1 | 63 (57 to 69) | 58 (54 to 61) | 71 (57 to 82) |
| A/H3N2 - Day 22 | 99 (97 to 100) | 99 (98 to 100) | 65 (51 to 78) |
| B - Day 1 | 25 (20 to 31) | 23 (20 to 27) | 22 (12 to 35) |
| B - Day 22 | 78 (72 to 83) | 92 (90 to 94) | 22 (12 to 35) |
As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer \<10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.
| Percentages of subjects | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| A/H1N1 | 78 (72 to 83) | 75 (71 to 78) | 0 (0 to 6) |
| A/H3N2 | 59 (53 to 66) | 68 (64 to 71) | 0 (0 to 6) |
| B | 51 (45 to 58) | 68 (65 to 72) | 0 (0 to 6) |
The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.
| Subjects | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Injection site Pain | 1158 | 893 | 375 |
| Injection site Erythema | 510 | 492 | 391 |
| Injection site Induration | 239 | 207 | 101 |
| Injection site Ecchymosis | 143 | 110 | 147 |
| Injection site Swelling | 218 | 181 | 103 |
| Chills | 210 | 211 | 223 |
| Malaise | 290 | 259 | 237 |
| Myalgia | 450 | 364 | 275 |
| Arthralgia | 108 | 111 | 125 |
| Headache | 564 | 551 | 592 |
| Sweating | 124 | 122 | 120 |
| Fatigue | 390 | 404 | 384 |
| Fever (>= 38 C) | 27 | 21 | 15 |
| Oral Temp. (< 38 C) | 3786 | 3648 | 3879 |
| Stayed home due to Reactions (N=3781, 3651, 3867) | 42 | 62 | 42 |
| Analgesic medicines used | 394 | 397 | 386 |
Collected over Serious Adverse Events were collected throughout the study period (i.e., 6 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CCI Vaccine | — | 42/3,813 (1.1%) | 1,949/3,813 (51.1%) |
| IVV Vaccine | — | 35/3,669 (1%) | 1,703/3,669 (46.4%) |
| Placebo | — | 38/3,894 (1%) | 1,387/3,894 (35.6%) |
| Event | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| AppendicitisInfections and infestations | 1/3813 | 1/3669 | 3/3894 |
| Haemorrhagic Ovarian CystReproductive system and breast disorders | 0/3813 | 2/3669 | 0/3894 |
| Nasal Septum DeviationRespiratory, thoracic and mediastinal disorders | 1/3813 | 2/3669 | 0/3894 |
| Ankle FractureInjury, poisoning and procedural complications | 2/3813 | 0/3669 | 1/3894 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 2/3813 | 0/3669 | 2/3894 |
| PharyngitisInfections and infestations | 0/3813 | 0/3669 | 2/3894 |
| PneumoniaInfections and infestations | 0/3813 | 1/3669 | 2/3894 |
| Back PainMusculoskeletal and connective tissue disorders | 0/3813 | 0/3669 | 2/3894 |
| Vertigo PositionalEar and labyrinth disorders | 0/3813 | 1/3669 | 0/3894 |
| Abdominal PainGastrointestinal disorders | 1/3813 | 1/3669 | 0/3894 |
| Event | CCI Vaccine | IVV Vaccine | Placebo |
|---|---|---|---|
| Injection Site PainGeneral disorders | 1158/3813 | 893/3669 | 375/3894 |
| HeadacheNervous system disorders | 571/3813 | 554/3669 | 597/3894 |
| Injection Site ErythemaGeneral disorders | 510/3813 | 492/3669 | 391/3894 |
| MyalgiaMusculoskeletal and connective tissue disorders | 451/3813 | 369/3669 | 278/3894 |
| FatigueGeneral disorders | 390/3813 | 404/3669 | 386/3894 |
| MalaiseGeneral disorders | 290/3813 | 260/3669 | 238/3894 |
| Injection Site IndurationGeneral disorders | 239/3813 | 207/3669 | 101/3894 |
| ChillsGeneral disorders | 212/3813 | 212/3669 | 225/3894 |
| Injection Site SwellingGeneral disorders | 218/3813 | 181/3669 | 103/3894 |
| Age, Continuous(years) | CCI Vaccine | IVV Vaccine | Placebo | Total |
|---|---|---|---|---|
| Mean | 32.7 ± 10.1 | 33.0 ± 10.2 | 32.7 ± 10.2 | 32.8 ± 10.2 |
| Sex/Gender, Customized(Subjects) | CCI Vaccine | IVV Vaccine | Placebo | Total |
|---|---|---|---|---|
| Female | 2088 | 2026 | 2176 | 6290 |
| Male | 1740 | 1649 | 1722 | 5111 |
| Not Available | 0 | 1 | 2 | 3 |
The record gives a start of Oct 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 4 years 6 months after primary completion. A results delay was requested in Mar 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.